Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. is listed today as Palvella Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2019 | $32 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Jun 2016 | $17 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2014 | $40 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pieris Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).
SEC Form D · Nov 2019
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2019
That is all the official record says: Pieris Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Pieris Pharmaceuticals, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock (Form 3, 2023) | SEC Form 3 |
| Biotechnology Value Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Biotechnology Value Trading Fund OS LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock (Form 3, 2023) | SEC Form 3 |
| BVF GP Holdings LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| BVF I GP LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| BVF II GP LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock (Form 3, 2023) | SEC Form 3 |
| BVF Inc/il | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| BVF Partners L P/il | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| BVF Partners OS Ltd. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock (Form 3, 2023) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Palvella Therapeutics, Inc. shares, as of Sep 30, 2026.
- Jennison Associates LLC$152 M7.54%
- Montanova Capital, LLC$144 M7.15%
- BlackRock, Inc.$137 M6.77%
- Frazier Life Sciences Management, L.P.$122 M6.04%
- First Light Asset Management, LLC$101 M5.02%
- State Street Corp$86 M4.27%
- BVF Inc/il$84 M4.15%
- Price T Rowe Associates Inc /MD/$82 M4.05%
- Vanguard Capital Management LLC$75 M3.70%
- Westfield Capital Management Co LP$55 M2.71%
- Federated Hermes, Inc.$46 M2.27%
- Marshall Wace, LLP$45 M2.26%
- Invesco Ltd.$43 M2.14%
- Geode Capital Management, LLC$43 M2.13%
- Frontier Capital Management Co LLC$38 M1.89%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ahmed S. Mousa | Executive officer | Nov 2019 |
| Hitto R. Kaufmann, Ph.D. | Executive officer | Nov 2019 |
| Stephen S. Yoder | Executive officer | Nov 2019 |
| Tom R. Bures | Executive officer | Nov 2019 |
| Darlene S. Deptula-Hicks | Executive officer | Jun 2016 |
| Darlene M. Deptula-Hicks | Acting Chief Financial Officer | Dec 2014 |
| Ann S. Barbier, M.D., Ph.D. | Director | Nov 2019 |
| Christopher S. Kiritsy | Director | Nov 2019 |
| James S. Geraghty | Director | Nov 2019 |
| Jean-Pierre S. Bizzari, M.D. | Director | Nov 2019 |
| Matthew L. Sherman, M.D. | Director | Nov 2019 |
| Maya R. Said, Sc.D. | Director | Nov 2019 |
| Michael S. Richman | Director | Nov 2019 |
| Peter S. Kiener, D.Phil. | Director | Nov 2019 |
| Stephen S. Yoder | Director | Nov 2019 |
| Chau S. Khuong | Director | Jun 2016 |
| Jean-Pierre S. Bizzari | Director | Jun 2016 |
| Steven S. Prelack | Director | Jun 2016 |
| Chau M. Khuong | Chairman of the Board of Directors | Dec 2014 |
| Christina M. Takke | Director | Dec 2014 |
| Michael M. Richman | Director | Dec 2014 |
| Steven M. Prelack | Director | Dec 2014 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.